ACCOUNTS - Final Accounts preparation


Caseware UK (AP4) 2018.0.196 2018.0.196 2019-04-302019-04-30The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.truefalseNo description of principal activityfalse2018-05-01 10127417 2018-05-01 2019-04-30 10127417 2017-05-01 2018-04-30 10127417 2019-04-30 10127417 2018-04-30 10127417 2017-05-01 10127417 c:Director1 2018-05-01 2019-04-30 10127417 d:Buildings d:ShortLeaseholdAssets 2018-05-01 2019-04-30 10127417 d:Buildings d:ShortLeaseholdAssets 2019-04-30 10127417 d:Buildings d:ShortLeaseholdAssets 2018-04-30 10127417 d:PlantMachinery 2018-05-01 2019-04-30 10127417 d:PlantMachinery 2019-04-30 10127417 d:PlantMachinery 2018-04-30 10127417 d:PlantMachinery d:OwnedOrFreeholdAssets 2018-05-01 2019-04-30 10127417 d:MotorVehicles 2018-05-01 2019-04-30 10127417 d:MotorVehicles 2019-04-30 10127417 d:MotorVehicles 2018-04-30 10127417 d:MotorVehicles d:OwnedOrFreeholdAssets 2018-05-01 2019-04-30 10127417 d:OfficeEquipment 2018-05-01 2019-04-30 10127417 d:OfficeEquipment 2019-04-30 10127417 d:OfficeEquipment 2018-04-30 10127417 d:OfficeEquipment d:OwnedOrFreeholdAssets 2018-05-01 2019-04-30 10127417 d:ComputerEquipment 2018-05-01 2019-04-30 10127417 d:ComputerEquipment 2019-04-30 10127417 d:ComputerEquipment 2018-04-30 10127417 d:ComputerEquipment d:OwnedOrFreeholdAssets 2018-05-01 2019-04-30 10127417 d:OwnedOrFreeholdAssets 2018-05-01 2019-04-30 10127417 d:CopyrightsPatentsTrademarksServiceOperatingRights 2018-05-01 2019-04-30 10127417 d:CopyrightsPatentsTrademarksServiceOperatingRights 2019-04-30 10127417 d:CopyrightsPatentsTrademarksServiceOperatingRights 2018-04-30 10127417 d:CopyrightsPatentsTrademarksServiceOperatingRights 2017-05-01 10127417 d:CurrentFinancialInstruments 2019-04-30 10127417 d:CurrentFinancialInstruments 2018-04-30 10127417 d:Non-currentFinancialInstruments 2019-04-30 10127417 d:Non-currentFinancialInstruments 2018-04-30 10127417 d:CurrentFinancialInstruments d:WithinOneYear 2019-04-30 10127417 d:CurrentFinancialInstruments d:WithinOneYear 2018-04-30 10127417 d:Non-currentFinancialInstruments d:AfterOneYear 2019-04-30 10127417 d:Non-currentFinancialInstruments d:AfterOneYear 2018-04-30 10127417 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2019-04-30 10127417 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2018-04-30 10127417 d:ShareCapital 2019-04-30 10127417 d:ShareCapital 2018-04-30 10127417 d:SharePremium 2019-04-30 10127417 d:SharePremium 2018-04-30 10127417 d:RetainedEarningsAccumulatedLosses 2019-04-30 10127417 d:RetainedEarningsAccumulatedLosses 2018-04-30 10127417 d:AcceleratedTaxDepreciationDeferredTax 2019-04-30 10127417 d:AcceleratedTaxDepreciationDeferredTax 2018-04-30 10127417 d:TaxLossesCarry-forwardsDeferredTax 2019-04-30 10127417 d:TaxLossesCarry-forwardsDeferredTax 2018-04-30 10127417 c:FRS102 2018-05-01 2019-04-30 10127417 c:AuditExempt-NoAccountantsReport 2018-05-01 2019-04-30 10127417 c:FullAccounts 2018-05-01 2019-04-30 10127417 c:PrivateLimitedCompanyLtd 2018-05-01 2019-04-30 10127417 d:WithinOneYear 2019-04-30 10127417 d:WithinOneYear 2018-04-30 10127417 d:BetweenOneFiveYears 2019-04-30 10127417 d:BetweenOneFiveYears 2018-04-30 10127417 d:MoreThanFiveYears 2019-04-30 10127417 d:MoreThanFiveYears 2018-04-30 10127417 d:HirePurchaseContracts d:WithinOneYear 2019-04-30 10127417 d:HirePurchaseContracts d:WithinOneYear 2018-04-30 10127417 d:HirePurchaseContracts d:BetweenOneFiveYears 2019-04-30 10127417 d:HirePurchaseContracts d:BetweenOneFiveYears 2018-04-30 iso4217:GBP

Registered number: 10127417










PEARMINE HEALTH LTD








UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2019

 
PEARMINE HEALTH LTD
REGISTERED NUMBER: 10127417

BALANCE SHEET
AS AT 30 APRIL 2019

2019
2018
Note
£
£

Fixed assets
  

Intangible assets
 4 
5,250
6,000

Tangible assets
 5 
83,896
102,765

  
89,146
108,765

Current assets
  

Stocks
 6 
128,206
86,976

Debtors: amounts falling due within one year
 7 
113,767
118,090

Cash at bank and in hand
 8 
45,934
93,226

  
287,907
298,292

Creditors: amounts falling due within one year
 9 
(138,750)
(147,399)

Net current assets
  
 
 
149,157
 
 
150,893

Total assets less current liabilities
  
238,303
259,658

Creditors: amounts falling due after more than one year
 10 
(184,592)
(185,072)

Provisions for liabilities
  

Deferred tax
 13 
(13,434)
(15,662)

  
 
 
(13,434)
 
 
(15,662)

Net assets
  
40,277
58,924


Capital and reserves
  

Called up share capital 
  
101
101

Share premium account
  
79,999
79,999

Profit and loss account
  
(39,823)
(21,176)

  
40,277
58,924


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Page 1

 
PEARMINE HEALTH LTD
REGISTERED NUMBER: 10127417

BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2019

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
M Ley
Director

Date: 30 January 2020

Page 2

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

1.


General information

Pearmine Health Limited is a private company, limited by share capital and incorporated in England and Wales.
The Company's registered office and principal place of business is Unit 5 The Sidings, Top Station Road, Brackley, NN13 7UG.
The Company's principal activity is the development and manufacture of innovative products for the healthcare industry.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Page 3

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

2.Accounting policies (continued)

 
2.4

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.5

Finance costs

Finance costs are charged to the Statement of comprehensive income over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Borrowing costs

All borrowing costs are recognised in the Statement of comprehensive income in the year in which they are incurred.

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

2.Accounting policies (continued)

 
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 
2.9

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 5

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

2.Accounting policies (continued)


2.10
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Leashold improvements
-
over the length of the lease
Plant and machinery
-
20%
Motor vehicles
-
20%
Office equipment
-
20%
Computer equipment
-
20%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of comprehensive income.

 
2.11

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first outbasis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.12

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.13

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.14

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 6

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

2.Accounting policies (continued)

 
2.15

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to the Statement of comprehensive income in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Balance sheet.

 
2.16

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

 
2.17

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 11 (2018 - 8).

Page 7

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

4.


Intangible assets




Trademarks

£



Cost


At 1 May 2018
7,500



At 30 April 2019

7,500



Amortisation


At 1 May 2018
1,500


Charge for the year
750



At 30 April 2019

2,250



Net book value



At 30 April 2019
5,250



At 30 April 2018
6,000

Page 8

 


 
PEARMINE HEALTH LTD


 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019


5.


Tangible fixed assets






Leasehold improvements
Plant and machinery
Motor vehicles
Office equipment
Computer equipment
Total

£
£
£
£
£
£



Cost or valuation


At 1 May 2018
8,116
87,675
11,558
2,303
3,815
113,467


Additions
5,720
2,950
-
7,937
309
16,916


Disposals
-
(3,446)
(11,558)
-
-
(15,004)



At 30 April 2019

13,836
87,179
-
10,240
4,124
115,379



Depreciation


At 1 May 2018
358
8,009
1,541
485
309
10,702


Charge for the year on owned assets
2,576
17,288
771
1,810
820
23,265


Disposals
-
(172)
(2,312)
-
-
(2,484)



At 30 April 2019

2,934
25,125
-
2,295
1,129
31,483



Net book value



At 30 April 2019
10,902
62,054
-
7,945
2,995
83,896



At 30 April 2018
7,758
79,666
10,017
1,818
3,506
102,765

Page 9

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

6.


Stocks

2019
2018
£
£

Stocks
128,206
86,976

128,206
86,976



7.


Debtors

2019
2018
£
£

Trade debtors
80,264
86,303

Other debtors
25,764
25,190

Prepayments and accrued income
7,739
6,597

113,767
118,090



8.


Cash and cash equivalents

2019
2018
£
£

Cash at bank and in hand
45,934
93,226

45,934
93,226



9.


Creditors: Amounts falling due within one year

2019
2018
£
£

Trade creditors
91,753
98,800

Corporation tax
1,552
-

Other taxation and social security
2,334
11,456

Obligations under finance lease and hire purchase contracts
1,551
1,551

Other creditors
21,917
21,257

Accruals and deferred income
19,643
14,335

138,750
147,399


Page 10

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019

10.


Creditors: Amounts falling due after more than one year

2019
2018
£
£

Other loans
183,300
181,500

Net obligations under finance leases and hire purchase contracts
1,292
3,572

184,592
185,072



11.


Loans


Analysis of the maturity of loans is given below:


2019
2018
£
£

Amounts falling due 2-5 years

Other loans
183,300
181,500


183,300
181,500

183,300
181,500


Interest is charged at 1% per annum.


12.


Hire purchase and finance leases


Minimum lease payments under hire purchase fall due as follows:

2019
2018
£
£


Within one year
1,551
1,551

Between 1-5 years
1,292
3,572

2,843
5,123


13.


Deferred taxation




2019
2018


£

£



At beginning of year
(15,662)
(2,356)


Charged to profit or loss
2,228
(13,306)



At end of year
(13,434)
(15,662)

Page 11

 
PEARMINE HEALTH LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019
 
13.Deferred taxation (continued)

The provision for deferred taxation is made up as follows:

2019
2018
£
£


Accelerated capital allowances
(14,116)
(15,662)

Short term timing differences
682
-

(13,434)
(15,662)


14.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company  to the fund and amounted to £613 (2017 - £nil) . Contributions totalling £1,357 (2017 - £nil) were payable to the fund at the balance sheet date and are included in creditors.


15.


Commitments under operating leases

At 30 April 2019 the Company had future minimum lease payments under non-cancellable operating leases as follows:

2019
2018
£
£


Not later than 1 year
20,500
20,500

Between 1 and 2 years
20,500
20,500

Not later than 5 years
35,875
56,375

76,875
97,375


16.


Related party transactions

At the year end the company owed, M Ley, a director, £20,265 (2018: £19,900), this amount includes interest charged at 1%, the balance is repayable upon demand.
During the period dividends of £33,101 (2018: £32,468) were paid to the directors.


17.


Controlling party

The company is controlled by M Ley, a director, by virtue of his shareholding.


Page 12